The Use of Arsenic Trioxide in Acute Promyelocytic Leukemia
Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.
Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide (ATO) in acute promyelocytic leukemia (APL).
Currently, all-trans retinoic acid (ATRA) plus chemotherapy is the gold standard for newly diagnosed APL patients demonstrating an 80% cure rate and typical toxicities (myelosuppression infections, hair loss). In the past 10 to 15 years, Lo-Coco says, ATO was suggested by Chinese investigators to show efficacy in APL with inferior toxicity.
Clinical Pearls
A phase III trial analyzing ATRA and ATO versus ATRA and idarubicin (AIDA) in newly diagnosed, non high-risk APL showed that the new strategy is at least equally effective.
- All-trans retinoic acid (ATRA) plus chemotherapy is the gold standard for newly diagnosed APL patients
- Arsenic trioxide has demonstrated efficacy in APL with inferior toxicity to ATRA
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
